A groundbreaking study spearheaded by Henry Daniell and his team at the University of Pennsylvania’s School of Dental Medicine has unveiled a promising new approach to combating head and neck squamous cell carcinoma (HNSCC) through the use of bioengineered chewing gum. This innovative research, recently published in Scientific Reports, highlights the gum’s ability to substantially reduce the presence of three microbes strongly linked with HNSCC, potentially heralding a new era of accessible and effective therapies for this challenging cancer type.
HNSCC, primarily developing in the mucosal linings of the mouth and throat, remains a formidable health challenge worldwide due to its aggressive nature and poor prognosis when detected late. Despite advances in oncology, recent pharmaceutical developments have struggled to meaningfully enhance five-year survival rates or improve the quality of life for patients suffering from this malignancy. Daniell underscores the urgent necessity for therapies that specifically target microbial contributors to cancer progression, paving the way for a more tailored, multifaceted treatment landscape.
Building on prior work involving a plant-based chewing gum derived from lablab beans and enriched with FRIL, a naturally occurring antiviral protein, Daniell’s study delves into the gum’s effects on key oncogenic microbes within oral environments. The three focal microorganisms—human papilloma virus (HPV), along with two bacterial species, Porphyromonas gingivalis and Fusobacterium nucleatum—are increasingly recognized not merely as coincidental inhabitants but as active facilitators in the carcinogenesis and progression of HNSCC.
HPV infection has gained particular attention due to its rapidly increasing role in oropharyngeal cancers worldwide. Epidemiological data underscore a direct correlation between HPV presence and a surge in oropharyngeal carcinoma cases. Meanwhile, P. gingivalis and F. nucleatum, anaerobic bacteria frequently present in periodontal diseases, have been implicated in exacerbating oral cancer outcomes. The persistent colonization of these bacteria is linked to inflammation-mediated tumorigenesis, diminished treatment response, and reduced survival rates, especially in the recurrent and metastatic settings.
Daniell’s team utilized clinical saliva and oral rinse samples from HNSCC patients to evaluate microbial load before and after treatment with the bioengineered gums. Remarkably, the lablab bean gum extracts containing FRIL achieved a 93% reduction in HPV levels in saliva and an 80% decrease in oral rinse samples. These antiviral properties mark a significant stride in non-invasive, patient-friendly cancer adjunct therapies aimed at directly diminishing viral oncogenic drivers.
To further enhance the therapeutic profile, the researchers introduced protegrin—an antimicrobial peptide with potent bactericidal activity—into the gum framework. Protegrin’s inclusion proved transformative, driving P. gingivalis and F. nucleatum levels down to virtually undetectable amounts following a single dose application. This selective antimicrobial effect is critically distinct from conventional cancer therapies such as radiation, which indiscriminately destroy beneficial oral microbiota and inadvertently foster opportunistic infections, notably with Candida albicans.
The significance of these findings resonates profoundly within the context of global cancer epidemiology. Lip and oral cavity cancers were ranked as the seventh leading type in incidence and mortality rates among adolescents, young adults, and middle-aged populations worldwide in 2022. Current treatment modalities often fail to address the microbial dimension of HNSCC pathogenesis, underscoring Daniell’s gum formulation as a potentially transformative prophylactic and adjuvant treatment modality.
Importantly, the gum’s specificity in targeting pathogenic microbes while sparing commensal oral flora addresses a critical shortcoming of prevailing antimicrobial approaches. Preservation of the beneficial microbiome is fundamental for maintaining oral homeostasis, immunity, and overall health. The ability to reduce carcinogenic microbes without collateral damage represents a paradigm shift in cancer supportive care.
The study’s ex vivo design—which analyzed clinical samples outside the living body—provides strong proof-of-concept evidence, but further clinical trials are imperative to translate these promising results into viable, widely accessible therapies. Daniell advocates for the advancement of this technology into human trials as adjuvant therapies alongside existing treatment regimens or as preventive measures aimed at reducing infection and transmission risks in at-risk populations.
These findings open exciting avenues for bioengineering and pharmaceutical innovation, demonstrating how natural plant-based platforms can be harnessed to develop next-generation biologics with dual antiviral and antibacterial properties. Beyond cancer, such strategies might well extend to combat microbial drivers of other chronic diseases, given the centrality of the microbiome in human health and disease.
Henry Daniell, holding the W.D. Miller Professorship in the Department of Basic & Translational Sciences, emphasizes that the gum-based delivery system’s ease of use, affordability, and targeted efficacy could profoundly democratize access to cancer adjunct therapies, especially in low-resource settings where advanced pharmaceutical interventions remain scarce.
The multidisciplinary collaboration among Penn Dental Medicine, the University of Kansas Medical Center, UCLA, and the Veterans Administration Greater Los Angeles Healthcare System highlights the compelling synergy between innovative materials science, microbiology, and clinical oncology necessary to pioneer such novel therapeutic modalities.
Funding support from the NIH, David Geffen School of Medicine at UCLA, and the National Cancer Institute Cancer Center reflects a robust commitment from leading health agencies to back groundbreaking explorations that challenge traditional paradigms and aspire to elevate patient outcomes in head and neck cancers.
As this research progresses, the prospect of mitigating cancer progression through a simple, bioengineered chewing gum merges cutting-edge scientific innovation with practical patient care, symbolizing a hopeful advance toward more effective, less toxic cancer prevention and management strategies.
Subject of Research: Human tissue samples
Article Title: Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes
News Publication Date: 9-Feb-2026
Web References: 10.1038/s41598-026-39062-w
Keywords: Head and neck cancer, Oral cancer, Antiviral activity, Antibiotic activity, Antivirals, Saliva
Tags: bioengineered chewing gum for oral cancerbioengineered natural products in oncologychewing gum as drug delivery systemFRIL protein in cancer therapyhead and neck squamous cell carcinoma treatmentHPV-related oral cancer preventioninnovative cancer treatment researchmicrobial reduction in HNSCCnovel therapies for head and neck canceroral microbiome targeting cancerplant-based antiviral chewing gumUniversity of Pennsylvania dental medicine study
